Country for PR: United Kingdom
Contributor: PR Newswire Europe
Saturday, March 26 2022 - 00:07
Abcam the most awarded company at 2022 industry awards
CAMBRIDGE, England, March 25, 2022 /PRNewswire-AsiaNet/ --

Abcam ( (AIM:ABC); (NASDAQ:ABCM), today announced 
that it has received six recognitions from CiteAb at their annual industry 
awards (, the highest of any participant 
evaluated this year. This record number of acknowledgments follows a year of 
substantial investment for Abcam to enable life sciences researchers from 
academia and industry to advance discoveries and deliver faster breakthroughs. 

First and foremost, Abcam was recognized for its initiatives to improve 
standards in the reagent industry. Its "Recombinant Multiclonal" range, which 
combines the benefits of recombinant monoclonal and polyclonal antibodies, was 
awarded "Innovation of the Year" by a panel of experts while Abcam was highly 
commended in the "Recombinant Antibody Supplier of the Year" category. The 
Company also won the "Supplier Succeeding in KO Validation" award for its 
antibody validation program 
( All three 
awards demonstrate Abcam's commitment to continually improving scientific 
reproducibility in life sciences, which benefits the research community and 
society globally. 

Prof. Giovanna Roncador, Head of the Monoclonal Antibodies Unit/Biotechnology 
Program at the Spanish National Cancer Research Center (CNIO), Founder and 
Chair of EuroMabNet and recipient of the 2022 CiteAb award for "Significant 
Individual Impact 
said: "As a cancer researcher and antibody engineer, I firmly believe that 
advancing science goes hand in hand with improving standards for reagent 
quality. I am delighted but not surprised to see Abcam's success in the CiteAb 
Awards, as, this year again, they have taken a number of strides forward to 
deliver the scientific community the tools they need for success."

Dr. Alejandra Solache, SVP Research and Development at Abcam and recipient of 
the 2021 CiteAb award for "Significant Individual Impact 
(" commented: "We are excited to see our 
dedication to delivering higher standards being acknowledged as we continually 
look for new ways in which we can break barriers and set new industry standards 
for improving reproducibility in science. Thank you to CiteAb, the judging 
panels and the researchers with whom we share the same passion to drive life 
sciences forward." 

Finally, this year's CiteAb awards also recognize Abcam's effort to address the 
growing demand of the sector for high-performance, reproducible, off-the-shelf 
assays with the acquisition of BioVision for $340M 
( Offering a platform for greater innovation 
and increasing access to biochemical assays and cellular assays, the deal is 
recognized for its potential to lay the foundations for future positive impact 
across the life sciences sector.

Abcam's 2022 full list of recognitions include: 

Acquisition of the Year 
( – Winner 
Innovation of the Year ( – 
Winner (Recombinant Multiclonal range)
Supplier Succeeding in KO validation 
( – 
Recombinant Antibody Supplier of the Year 
- Highly Commended
Supplier Succeeding in Cancer Research 
( - 
Highly Commended
Supplier Succeeding in Sars-Cov-2 research 
- Highly Commended

About Abcam plc

As a global life sciences company, Abcam identifies, develops, and distributes 
high-quality biological reagents and tools that are crucial to research, drug 
discovery and diagnostics. Working across the industry, the Company supports 
life scientists to achieve their mission, faster. 

Abcam partners with life sciences organizations to co-create novel binders for 
use in drug discovery, in vitro diagnostics and therapeutics, driven by the 
Company's proprietary discovery platforms and world-leading antibody expertise. 

By constantly innovating its binders and assays, Abcam is helping advance the 
global understanding of biology and causes of disease, which enables new 
treatments and improved health. The Company's pioneering data-sharing approach 
gives scientists increased confidence in their results by providing validation, 
user comments and peer-reviewed citations for its 90,000 products. 

With a direct presence in America, Asia and Europe, many of Abcam's over 
1,700-strong team are located in the world's leading life sciences research 
hubs, complementing a global network of service and support. 

To find out more, please visit ( and (

Logo -